Cargando…

Efficacy and safety of treatments in newly diagnosed adult primary immune thrombocytopenia: A systematic review and network meta-analysis

BACKGROUND: Immune thrombocytopenia is an autoimmune disease characterised by decreased platelet count. In recent years, novel therapeutic regimens have been investigated in randomised controlled trials (RCTs). We aimed to compare the efficacy and safety of different treatments in newly diagnosed ad...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yun, Sheng, Lei, Han, Fengjiao, Guo, Qiuyu, Zhang, Zihan, Hou, Yu, Feng, Qi, Zhou, Hai, Ji, Xuebin, Peng, Jun, Hou, Ming, Xu, Miao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791309/ https://www.ncbi.nlm.nih.gov/pubmed/36578882 http://dx.doi.org/10.1016/j.eclinm.2022.101777

Ejemplares similares

Romiplostim in children with newly diagnosed or persistent primary immune thrombocytopenia
por: Grainger, John D., et al.
Publicado: (2021)

Adolescents and young adults with newly diagnosed primary immune thrombocytopenia
por: Schifferli, Alexandra, et al.
Publicado: (2023)

T cell immune abnormalities in immune thrombocytopenia
por: Ji, Xuebin, et al.
Publicado: (2014)

Contributions of T Lymphocyte Abnormalities to Therapeutic Outcomes in Newly Diagnosed Patients with Immune Thrombocytopenia
por: Zhao, Zhenhua, et al.
Publicado: (2015)

Regulatory and Memory B Lymphocytes in Children With Newly Diagnosed Immune Thrombocytopenia
por: Zahran, Asmaa M., et al.
Publicado: (2017)

A case of newly diagnosed immune thrombocytopenia in the COVID-19 era
por: Clerici, Bianca, et al.
Publicado: (2020)

Association between P-Selectin Autoantibody Positive and Response to Steroid Treatment in Newly Diagnosed Immune Thrombocytopenia Patients
por: Wang, Li, et al.
Publicado: (2022)

Effectiveness and Safety of Romiplostim Among Patients with Newly Diagnosed, Persistent and Chronic Immune Thrombocytopenia in European Clinical Practice
por: Snell Taylor, Sara J., et al.
Publicado: (2021)

The Efficacy of High-Dose Dexamethasone vs. Other Treatments for Newly Diagnosed Immune Thrombocytopenia: A Meta-Analysis
por: Xiao, Qirong, et al.
Publicado: (2021)

Platelet to Lymphocyte Ratio and Glucocorticoid Resistance in Newly Diagnosed Primary Immune Thrombocytopenia: A Retrospective Cohort Study
por: Wang, Lin-Hui, et al.
Publicado: (2019)

Clonal hematopoiesis in primary immune thrombocytopenia
por: Wang, Yanming, et al.
Publicado: (2022)

Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia
por: Cines, Douglas B., et al.
Publicado: (2017)

Short-term dose-escalated romiplostim for preparing an adult patient with persistent newly diagnosed primary immune thrombocytopenia for splenectomy
por: Murray, Nigel P., et al.
Publicado: (2020)

Biomarkers for immune thrombocytopenia
por: Yu, Lingjia, et al.
Publicado: (2015)

Hypovitaminosis D Influences the Clinical Presentation of Immune Thrombocytopenia in Children with Newly Diagnosed Disease
por: Petrovic, Davor, et al.
Publicado: (2019)

Doppler ultrasound screening in patients with newly diagnosed heparin-induced thrombocytopenia
por: Harris, Elyse I., et al.
Publicado: (2021)

Newly Diagnosed Idiopathic Thrombocytopenia Post COVID-19 Vaccine Administration
por: Idogun, Precious O, et al.
Publicado: (2021)

How we treat primary immune thrombocytopenia in adults
por: Liu, Xin-guang, et al.
Publicado: (2023)

The effect of single course high dose dexamethasone on CD28/CTLA-4 balance in the treatment of patients with newly diagnosed primary immune thrombocytopenia
por: Guo, Xinhong, et al.
Publicado: (2015)

Immune Checkpoint-Related Gene Polymorphisms Are Associated With Primary Immune Thrombocytopenia
por: Wang, Shuwen, et al.
Publicado: (2021)

Efficacy and safety of thrombopoietin receptor agonists in patients with primary immune thrombocytopenia: A systematic review and meta-analysis
por: Wang, Li, et al.
Publicado: (2016)

ML-08 Safety and efficacy of consolidation cytarabine for newly-diagnosed primary central nervous system lymphoma
por: Sasaki, Nobuyoshi, et al.
Publicado: (2020)

Single course of high dose dexamethasone is more effective than conventional prednisolone therapy in the treatment of primary newly diagnosed immune thrombocytopenia
por: Mashhadi, Mohammad Ali, et al.
Publicado: (2012)

ESPED survey on newly diagnosed immune thrombocytopenia in childhood: how much treatment do we give?
por: von Lukowicz, Hannah, et al.
Publicado: (2021)

Efficacy and safety of eltrombopag in adult refractory immune thrombocytopenia
por: Kim, Yeo-Kyeoung, et al.
Publicado: (2015)

Clinical efficacy of high-dose dexamethasone with sequential prednisone maintenance therapy for newly diagnosed adult immune thrombocytopenia in a real-world setting
por: Xu, Jin, et al.
Publicado: (2021)

Efficacy and safety of bortezomib maintenance in patients with newly diagnosed multiple myeloma: a meta-analysis
por: Sun, Chun-yan, et al.
Publicado: (2017)

Comparison of up-front treatments for newly diagnosed immune thrombocytopenia -a systematic review and network meta-analysis
por: Arai, Yasuyuki, et al.
Publicado: (2018)

Clinical Epidemiology, Treatment Outcome and Mortality Rate of Newly Diagnosed Immune Thrombocytopenia in Adult Multicentre Study in Malaysia
por: Hamzah, Roszymah, et al.
Publicado: (2022)

The Efficacy and Safety of Cytarabine on Newly Diagnosed Primary Central Nervous System Lymphoma: A Systematic Review and Meta-Analysis
por: Zheng, Xiaohong, et al.
Publicado: (2020)

PB2307: A MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF ROMIPLOSTIM PLUS DEXAMETHASONE VS DEXAMETHASONE IN PATIENTS WITH NEWLY DIAGNOSED PRIMARY IMMUNE THROMBOCYTOPENIA
por: Mingot Castellano, M. E., et al.
Publicado: (2022)

Assessment of Health Status in Patients with Newly Diagnosed Chronic Obstructive Pulmonary Disease
por: Gao, Yongping, et al.
Publicado: (2013)

Long-term safety and efficacy of romiplostim for treatment of immune thrombocytopenia
por: Vishnu, Prakash, et al.
Publicado: (2016)

P1596: EFFICACY AND SAFETY OF QL0911 IN ADULT PATIENTS WITH CHRONIC PRIMARY IMMUNE THROMBOCYTOPENIA: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III TRIAL
por: Zhou, Hu, et al.
Publicado: (2023)

Low-dose intravenous immunoglobulin for children with newly diagnosed immune thrombocytopenia: protocol of a systematic review and meta-analysis
por: Ren, Xiangge, et al.
Publicado: (2023)

Efficacy and Safety of a New 10% Intravenous Immunoglobulin Product in Patients with Primary Immune Thrombocytopenia (ITP)
por: Hong, Junshik, et al.
Publicado: (2018)

Efficacy and safety of cyclosporine-based regimens for primary immune thrombocytopenia: a systematic review and meta-analysis
por: Li, Xiaojing, et al.
Publicado: (2023)

Cryptococcus albidus encephalitis in newly diagnosed HIV-patient and literature review()
por: Liu, Yang, et al.
Publicado: (2013)

Platelet desialylation correlates with efficacy of first-line therapies for immune thrombocytopenia
por: Tao, Lili, et al.
Publicado: (2017)

Comparison of the effectiveness and safety of perampanel and oxcarbazepine as monotherapy in children and adolescents with newly diagnosed focal epilepsy
por: Yi, Jia-Qin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_v0ji4pghgrbvlmh1l7182ur84s